A Phase 1a Study of CUSP06 in People With Ovarian or Endometrial Cancer

Full Title

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Purpose

Researchers are finding the best dose of CUSP06 to use in people with advanced ovarian or endometrial cancer. The people in this study have cancer that came back or keeps growing after treatment.

CUSP06 targets cells that have CDH6, a protein which plays a role in cancer cell growth. By destroying these cells, CUSP06 may help slow or stop the growth of your cancer. CUSP06 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have ovarian cancer or endometrial cancer that makes CDH6 and came back or keeps growing after treatment.
• Have completed prior anti-cancer treatment at least 4 weeks before getting CUSP06.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-608-2091.